OptiBiotix Health PLC SlimBiome® Medical update (7271V)
05 Diciembre 2019 - 01:00AM
UK Regulatory
TIDMOPTI
RNS Number : 7271V
OptiBiotix Health PLC
05 December 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Unflavoured SlimBiome(R) Medical granted medical device status
and CE mark
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skincare, announces that OptiBiotix has achieved medical device
status and a CE mark for an unflavoured version of SlimBiome(R)
Medical. This provides a product line extension to the existing
SlimBiome(R) Medical range which will be launched commercially in
H1 2020.
The decision to launch an unflavoured version of SlimBiome(R)
Medical allows OptiBiotix to extend its product offering and, when
used in combination with taste enhancement products such as the
Natural Flavour Boosters launched in Q4 2019, expands the choice of
flavours available to customers at a minimal cost to OptiBiotix.
The combination of the unflavoured SlimBiome(R) Medical with the
flavour boosters also represent cost savings to OptiBiotix as the
Company is not required to register new flavours individually as
medical devices thus saving time and money with future line
extensions.
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division, commented: "We are very pleased to have been granted a
medical device status and a CE mark for the second time over a
12-month period (RNS: 27.11.2019 - SlimBiome(R) granted medical
device status & CE mark). This line extension will help us
convert the commercial opportunities we are working on into
distribution agreements."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than 20 international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCCKQDPOBDDDBK
(END) Dow Jones Newswires
December 05, 2019 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024